See up to 3 months of OKYO. The 7-day demo opens the 1M and 3M ranges and puts OKYO on your watchlist.
Start 7-day demoLatest OKYO insider trades
About OKYO Pharma Ltd (OKYO)
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
- 5
- 2022
- XNAS
OKYO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 71,863 | $103K |
| Grant or award | 7 | 94,363 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
OKYO insider transactions (Form 4)
1818 Form 4 filings on record, the earliest from Jun 10, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John P. Brancaccio - Director | Open-market purchase | COMMON STOCK | 5,000 | $1.48 | $7K | |
| Robert John Dempsey - Officer | Open-market purchase | COMMON STOCK | 15,000 | $1.54 | $23K | |
| Gary S. Jacob - Officer | Open-market purchase | COMMON STOCK | 3,500 | $1.40 | $5K | |
| Gabriele M. Cerrone - Director | Open-market purchase | COMMON STOCK | 25,000 | $1.40 | $35K | |
 Flavio Mantelli - Officer | Open-market purchase | COMMON STOCK | 20,000 | $1.40 | $28K | |
| Rajkumar V. Patil - Officer | Open-market purchase | COMMON STOCK | 3,363 | $1.49 | $5K | |
| Rajkumar V. Patil - Officer | Grant or award | COMMON STOCK | 3,363 | $1.49 | $5K | |
| Robert John Dempsey - Officer | Grant or award | COMMON STOCK | 15,000 | $1.54 | $23K | |
| Gabriele M. Cerrone - Director | Grant or award | COMMON STOCK | 22,500 | $1.45 | $33K | |
| Gary S. Jacob - Officer | Grant or award | COMMON STOCK | 3,500 | $1.40 | $5K | |
| John P. Brancaccio - Director | Grant or award | COMMON STOCK | 5,000 | $1.48 | $7K | |
| Flavio Mantelli - Officer | Grant or award | COMMON STOCK | 20,000 | $1.40 | $28K | |
| Gabriele M. Cerrone - Director | Grant or award | COMMON STOCK | 25,000 | $1.40 | $35K | |
 Bernard Denoyer - Director | Grant or award | Option | 3,500 | $1.85 | $6K | |
| John P. Brancaccio - Director | Grant or award | Option | 6,500 | $1.85 | $12K | |
| Willy Jules Simon - Director | Grant or award | Option | 6,500 | $1.85 | $12K | |
| Keeren Rameshchandra Shah - Officer | Grant or award | Option | 40,000 | $1.85 | $74K | |
| Gabriele M. Cerrone - Director | Grant or award | COMMON STOCK | 300,000 | $1.72 | $516K |
OKYO insider trading FAQ
What is the latest insider trade for OKYO?
OKYO Pharma Ltd (OKYO) had 13 insider filings in the last 90 days, with the most recent on 2026-08-07. The full record for OKYO runs to 18 Form 4 filings, the earliest from 2026-06-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying OKYO stock?
6 insider purchases of OKYO were filed in the last 90 days, totaling $103K.
How many insiders are selling OKYO stock?
No insider sales of OKYO were filed in the last 90 days.
Where can I see OKYO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects OKYO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - John P. Brancaccio view on EDGAR
- - Robert John Dempsey view on EDGAR
- - Gary S. Jacob view on EDGAR
- - Gabriele M. Cerrone view on EDGAR
- - Flavio Mantelli view on EDGAR
- - Rajkumar V. Patil view on EDGAR
- - Rajkumar V. Patil view on EDGAR
- - Robert John Dempsey view on EDGAR
- - Gabriele M. Cerrone view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where OKYO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow OKYO with a 7-day demo
- OKYO on your watchlist
- Every OKYO Form 4 filing on record
- Up to 3 months of OKYO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
